Education
About Us
Working with TipRanks
Follow Us
Ensysce Biosciences (ENSC)
NASDAQ:ENSC
ENSC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.62 - $14.68
Previous CloseN/A
Volume52.20K
Average Volume (3M)608.05K
Market Cap
$6.20M
Enterprise Value$2.77M
Total Cash (Recent Filing)$2.21M
Total Debt (Recent Filing)$424.52K
Price to Earnings (P/E)―
Beta1.73
Next Earnings
Nov 17, 2025EPS Estimate
-0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.79
Shares Outstanding2,968,444
10 Day Avg. Volume51,807
30 Day Avg. Volume608,051
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.45
Enterprise Value/Revenue0.37
Enterprise Value/Gross Profit5.05
Enterprise Value/Ebitda-0.42
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Ensysce Biosciences News
ENSC FAQ
What was Ensysce Biosciences’s price range in the past 12 months?
Ensysce Biosciences lowest stock price was $1.62 and its highest was $14.68 in the past 12 months.
What is Ensysce Biosciences’s market cap?
Ensysce Biosciences’s market cap is $6.20M.
When is Ensysce Biosciences’s upcoming earnings report date?
Ensysce Biosciences’s upcoming earnings report date is Nov 17, 2025 which is in 76 days.
How were Ensysce Biosciences’s earnings last quarter?
Ensysce Biosciences released its earnings results on Aug 13, 2025. The company reported -$0.787 earnings per share for the quarter, beating the consensus estimate of -$1.015 by $0.228.
Is Ensysce Biosciences overvalued?
According to Wall Street analysts Ensysce Biosciences’s price is currently Overvalued.
Does Ensysce Biosciences pay dividends?
Ensysce Biosciences does not currently pay dividends.
What is Ensysce Biosciences’s EPS estimate?
Ensysce Biosciences’s EPS estimate is -0.83.
How many shares outstanding does Ensysce Biosciences have?
Ensysce Biosciences has 2,968,444 shares outstanding.
What happened to Ensysce Biosciences’s price movement after its last earnings report?
Ensysce Biosciences reported an EPS of -$0.787 in its last earnings report, beating expectations of -$1.015. Following the earnings report the stock price went up 2.871%.
Which hedge fund is a major shareholder of Ensysce Biosciences?
Currently, no hedge funds are holding shares in ENSC
Company Description
Ensysce Biosciences
Ensysce Biosciences (ENSC) is a biotechnology company focused on developing innovative solutions for pain management and the treatment of opioid use disorders. The company operates in the pharmaceutical sector and is dedicated to addressing the opioid crisis through its proprietary technology platforms, including TAAP (Trypsin Activated Abuse Protection) and MPAR (Multi-Pill Abuse Resistance). These platforms are designed to improve the safety and efficacy of prescription drugs, reducing the potential for abuse and addiction.
Technical Analysis
Galmed Pharmaceuticals
―
Aptevo Therapeutics
―
Enveric Biosciences
―
Revelation Biosciences
―
Tao Synergies
―
Ownership Overview
―
Insiders
0.30% Mutual Funds
5.54% Other Institutional Investors
94.08% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---